Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes
Synopsis
Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.
Avadel Pharmaceuticals Plc (AVDL) said on Friday that it has received an unsolicited proposal from H. Lundbeck A/S to acquire the drugmaker for up to $23 per share.
Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.
Alkermes (ALKS) decided to acquire all outstanding ordinary shares of Avadel for up to $20 per share in October. However, the board has not yet decided that the Lundbeck Proposal is indeed superior to the existing agreement with Alkermes and continues to be in support of the agreed-upon deal.
AVDL shares jumped 17% in the premarket session at the time of writing.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.